Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 16/9/2019
SIETES contiene 92806 citas

 
 
 1 a 20 de 118 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Walsh LK, Donelle J, Dodds L, Hawken S, Wilson K, Benchimol EI, Chakraborty P, Guttmann A, Kwong JC, MacDonald NE, Sprague AE, Top KA, Walker MC, Web SW, Fell DB. Health outcomes of young children born to mothers who received 2009 pandemic H1N1 influenza vaccination during pregnancy: retrospective cohort study. BMJ 2019;366:10 de julio. [Ref.ID 103171]
2. Cita con resumen
Young K. No evidence haloperidol helps in hospital delirium. Journal Watch 2019:3 de septiembre. [Ref.ID 103168]
3.Enlace a cita original Cita con resumen
Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]
4. Cita con resumen
Anónimo. Pour mieux soigner: des médicaments à écarter. Prescrire 2013;33:138-42. [Ref.ID 94882]
5. Cita con resumen
Anónimo. Gabapentin for pain. New evidence from hidden data. Therapeutics Initiative 2010;0:1-2. [Ref.ID 88272]
6. Cita con resumen
Anónimo. Merck Serono launches Ismigen in Argentina. Scrip 2009;3449:16. [Ref.ID 86071]
7. Cita con resumen
De Backer TLM, Stichele RHV, Van Bortel LM. Bias in benefit-risk appraisal in older products: the case of buflomedil for intermittent claudication. Drug Saf 2009;32:283-91. [Ref.ID 85762]
8.Tiene citas relacionadas Cita con resumen
Siegel M. Nicotine replacement therapy. Nicotine replacement, effective?. BMJ 2009;338:1030. [Ref.ID 85735]
9. Cita con resumen
Bertele V, Banzi R, Capasso F, Tafuri G, Trotta F, Apolone G, Garattini S. Haematological anticancer drugs in Europe: any added value at the time of approval?. Eur J Clin Pharmacol 2007;63:713-9. [Ref.ID 80479]
10. Cita con resumen
Anónimo. Buflomedil. Higher dose tablets withdrawn due to risk of suicide. WHO Pharmaceuticals Newsletter 2007;1:1. [Ref.ID 79562]
11. Cita con resumen
Anónimo. Danish industry report raises innovative medicines concerns. Scrip 2006;3124:4. [Ref.ID 76031]
12.Tiene citas relacionadas Cita con resumen
Lindholm LH, Carlberg B, Samuelsson O. ß blockers for the treatment of primary hypertension. Authors' reply. Lancet 2006;367:210. [Ref.ID 75996]
13.Enlace a cita originalTiene citas relacionadas Cita con resumen
Ball SG. ß blockers for the treatment of primary hypertension. Lancet 2006;367:209-10. [Ref.ID 75995]
14.Tiene citas relacionadas Cita con resumen
Cruickshank JM. ß blockers for the treatment of primary hypertension. Lancet 2006;367:209. [Ref.ID 75994]
15.Tiene citas relacionadas Cita con resumen
Khan N, McAlister F. ß blockers for the treatment of primary hypertension. Lancet 2006;367:208. [Ref.ID 75993]
16.Tiene citas relacionadas Cita con resumen
Raoult D. Are the clinical effects of homoeopathy placebo effects? Authors' reply. Lancet 2005;366:2085-6. [Ref.ID 75755]
17. Cita con resumen
Kapp C. SA health minister urged to stop vitamin-peddling doctor. Lancet 2005;366:1837-8. [Ref.ID 75507]
18. Cita con resumen
Ballarín E, Ibáñez L, Hernández JA, Force L, Laporte JR. Cyanamide-induced aplastic anemia. Eur J Clin Pharmacol 2005;61:467-9. [Ref.ID 74857]
19.Tiene citas relacionadas Cita con resumen
McCarthy M. Critics slam draft WHO report on homoeopathy. Lancet 2005;366:705-6. [Ref.ID 74683]
20. Cita con resumen
Anónimo. New medicines bill in Spain attacked from all sides. Scrip 2005;3072:4. [Ref.ID 74340]
Seleccionar todas
 
 1 a 20 de 118 siguiente >>